Tatara Therapeutics, a biotech developing redox-driven cancer therapies, has appointed a Director of in vivo Pharmacology to advance its FIRE (Ferrous Iron REactive) platform.
The new leadership strengthens Tatara’s ability to translate molecular innovation into differentiated oncology programs, accelerating the development of novel small molecules and ADCs targeting ferro-addicted tumours.





